Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in Biochem Pharmacol

Retrieve available abstracts of 13 articles:
HTML format



Single Articles


    October 2021
  1. VIGON L, Martinez-Roman P, Rodriguez-Mora S, Torres M, et al
    Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy.
    Biochem Pharmacol. 2021;192:114666.
    PubMed     Abstract available


    July 2021
  2. LU X, Yan G, Dawood M, Klauck SM, et al
    A novel moniliformin derivative as pan-inhibitor of histone deacetylases triggering apoptosis of leukemia cells.
    Biochem Pharmacol. 2021 Jul 12:114677. doi: 10.1016/j.bcp.2021.114677.
    PubMed     Abstract available


    June 2021
  3. KIM JH, Lee SJ, Kang KW, Lee BH, et al
    CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.
    Biochem Pharmacol. 2021;190:114658.
    PubMed     Abstract available


    April 2021
  4. WANG F, Huang J, Guo T, Zheng Y, et al
    Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Biochem Pharmacol. 2021 Apr 5:114538. doi: 10.1016/j.bcp.2021.114538.
    PubMed     Abstract available


  5. CHIOU JT, Lee YC, Huang CH, Wang LJ, et al
    Inhibition of Sp1-mediated survivin and MCL1 expression cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to human leukemia cells.
    Biochem Pharmacol. 2021 Apr 5:114544. doi: 10.1016/j.bcp.2021.114544.
    PubMed     Abstract available


    January 2021
  6. MARENSI V, Keeshan KR, MacEwan DJ
    Pharmacological impact of FLT3 mutations on receptor activity and responsiveness to tyrosine kinase inhibitors.
    Biochem Pharmacol. 2021;183:114348.
    PubMed     Abstract available


    December 2020
  7. NABERGOJ S, Markovic T, Avsec D, Gobec M, et al
    EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells.
    Biochem Pharmacol. 2020 Dec 2:114352. doi: 10.1016/j.bcp.2020.114352.
    PubMed     Abstract available


  8. RODRIGUES MAD, Pimenta MV, Costa IM, Zenatti PP, et al
    Influence of lysosomal protease sensitivity in the immunogenicity of the antitumor biopharmaceutical asparaginase.
    Biochem Pharmacol. 2020;182:114230.
    PubMed     Abstract available


  9. VIGON L, Rodriguez-Mora S, Luna A, Sandonis V, et al
    Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection.
    Biochem Pharmacol. 2020;182:114203.
    PubMed     Abstract available


    October 2020
  10. CARTER JL, Hege K, Kalpage HA, Edwards H, et al
    Targeting mitochondrial respiration for the treatment of acute myeloid leukemia.
    Biochem Pharmacol. 2020 Oct 1:114253. doi: 10.1016/j.bcp.2020.114253.
    PubMed     Abstract available


    May 2020
  11. LEE YC, Wang LJ, Huang CH, Chiou JT, et al
    Inhibition of EGFR pathway promotes the cytotoxicity of ABT-263 in human leukemia K562 cells by blocking MCL1 upregulation.
    Biochem Pharmacol. 2020 May 21:114047. doi: 10.1016/j.bcp.2020.114047.
    PubMed     Abstract available


    April 2020
  12. GBYLI R, Song Y, Halene S
    Humanized mice as preclinical models for myeloid malignancies.
    Biochem Pharmacol. 2020;174:113794.
    PubMed     Abstract available


    September 2019
  13. FARAONI I, Giansanti M, Voso MT, Lo-Coco F, et al
    Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders.
    Biochem Pharmacol. 2019;167:133-148.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: